The beneficial effects of recombinant ACE2 administration on human pulmonary arterial hypertension (101) and in lung lesions caused by viral infections (102, 103), support the relevance of sACE2 in blocking viral particles in preventing the interaction with transmembrane ACE2. This evidence concerns the gene ACE2 and viral infectious disease.